Skip to main content
Top
Published in: Digestive Diseases and Sciences 12/2021

01-12-2021 | Metastasis | Original Article

HIF1A-AS2 Promotes the Proliferation and Metastasis of Gastric Cancer Cells Through miR-429/PD-L1 Axis

Authors: Linsong Mu, Yeli Wang, Hailong Su, Yang Lin, Wu Sui, Xiang Yu, Zhongchuan Lv

Published in: Digestive Diseases and Sciences | Issue 12/2021

Login to get access

Abstract

Background

Gastric cancer (GC) is a common leading cause of cancer-related mortality of all malignancies. LncRNA hypoxia-inducible factor-1 alpha antisense RNA-2 (HIF1A-AS2) has been identified to involve in the development of GC. Therefore, we further explored the detailed molecular mechanism of HIF1A-AS2 in GC progression.

Methods

The expression of HIF1A-AS2, microRNA-429 (miR-429), and programmed cell death ligand 1 (PD-L1) was measured using quantitative real-time polymerase chain reaction (qRT-PCR) and western blot. Cell proliferation, migration, and invasion abilities were detected by Cell Counting Kit-8 (CCK-8) or transwell assay. The interaction between miR-429 and HIF1A-AS2 or PD-L1 was confirmed by luciferase reporter assay. Murine xenograft model was established to investigate the role of HIF1A-AS2 in vivo.

Results

HIF1A-AS2 was elevated in GC tissues and cell lines. Functional experiments showed that HIF1A-AS2 knockdown inhibited GC cell proliferation, migration, and invasion in vitro, as well as hindered tumor growth in vivo. Moreover, HIF1A-AS2 directly bound to miR-429 based on bioinformatics prediction and luciferase assay, and inhibition of miR-429 abolished the effects of HIF1A-AS2 knockdown on GC cells. Furthermore, miR-429 directly targeted PD-L1, and overexpression of miR-429 suppressed GC tumorigenesis via PD-L1. Besides that, PD-L1 also performed an oncogenic role in GC cell proliferation and metastasis. Additionally, HIF1A-AS2 could indirectly regulate PD-L1 expression via sponging miR-429.

Conclusion

HIF1A-AS2 is a dependable predictor of malignancy and prognosis in GC and functions as an oncogene to promote GC cell proliferation and metastasis by regulating miR-429/PD-L1 axis, indicating a new insight into the search for novel biomarkers and therapeutic strategies.
Appendix
Available only for authorised users
Literature
1.
go back to reference Herrero R, Park JY, Forman D. The fight against gastric cancer—the IARC Working Group report. Best Pract Res Clin Gastroenterol 2014;28:1107–1114CrossRef Herrero R, Park JY, Forman D. The fight against gastric cancer—the IARC Working Group report. Best Pract Res Clin Gastroenterol 2014;28:1107–1114CrossRef
2.
go back to reference Necula L, Matei L, Dragu D, Neagu AI, Mambet C, Nedeianu S et al. Recent advances in gastric cancer early diagnosis. World J Gastroenterol 2019;25:2029–2044CrossRef Necula L, Matei L, Dragu D, Neagu AI, Mambet C, Nedeianu S et al. Recent advances in gastric cancer early diagnosis. World J Gastroenterol 2019;25:2029–2044CrossRef
3.
go back to reference Chen DL, Zhang DS, Lu YX, Chen LZ, Zeng ZL, He MM et al. microRNA-217 inhibits tumor progression and metastasis by downregulating EZH2 and predicts favorable prognosis in gastric cancer. Oncotarget 2015;6:10868–10879CrossRef Chen DL, Zhang DS, Lu YX, Chen LZ, Zeng ZL, He MM et al. microRNA-217 inhibits tumor progression and metastasis by downregulating EZH2 and predicts favorable prognosis in gastric cancer. Oncotarget 2015;6:10868–10879CrossRef
4.
go back to reference Li J, Meng H, Bai Y, Wang K. Regulation of lncRNA and its role in cancer metastasis. Oncol Res 2016;23:205–217CrossRef Li J, Meng H, Bai Y, Wang K. Regulation of lncRNA and its role in cancer metastasis. Oncol Res 2016;23:205–217CrossRef
5.
go back to reference Mercer TR, Mattick JS. Structure and function of long noncoding RNAs in epigenetic regulation. Nat Struct Mol Biol 2013;20:300–307CrossRef Mercer TR, Mattick JS. Structure and function of long noncoding RNAs in epigenetic regulation. Nat Struct Mol Biol 2013;20:300–307CrossRef
6.
go back to reference Sun W, Yang Y, Xu C, Guo J. Regulatory mechanisms of long noncoding RNAs on gene expression in cancers. Cancer Genet 2017;216:105–110CrossRef Sun W, Yang Y, Xu C, Guo J. Regulatory mechanisms of long noncoding RNAs on gene expression in cancers. Cancer Genet 2017;216:105–110CrossRef
7.
go back to reference Peng WX, Koirala P, Mo YY. LncRNA-mediated regulation of cell signaling in cancer. Oncogene 2017;36:5661–5667CrossRef Peng WX, Koirala P, Mo YY. LncRNA-mediated regulation of cell signaling in cancer. Oncogene 2017;36:5661–5667CrossRef
8.
go back to reference Renganathan A, Felley-Bosco E. Long noncoding RNAs in cancer and therapeutic potential. Adv Exp Med Biol 2017;1008:199–222CrossRef Renganathan A, Felley-Bosco E. Long noncoding RNAs in cancer and therapeutic potential. Adv Exp Med Biol 2017;1008:199–222CrossRef
9.
go back to reference Thrash-Bingham CA, Tartof KD. aHIF: a natural antisense transcript overexpressed in human renal cancer and during hypoxia. J Natl Cancer Inst 1999;91:143–151CrossRef Thrash-Bingham CA, Tartof KD. aHIF: a natural antisense transcript overexpressed in human renal cancer and during hypoxia. J Natl Cancer Inst 1999;91:143–151CrossRef
10.
go back to reference Zhang Y, Zhang L, Wang Y, Ding H, Xue S, Yu H et al. KCNQ1OT1, HIF1A-AS2 and APOA1-AS are promising novel biomarkers for diagnosis of coronary artery disease. Clin Exp Pharmacol Physiol 2019;46:635–642CrossRef Zhang Y, Zhang L, Wang Y, Ding H, Xue S, Yu H et al. KCNQ1OT1, HIF1A-AS2 and APOA1-AS are promising novel biomarkers for diagnosis of coronary artery disease. Clin Exp Pharmacol Physiol 2019;46:635–642CrossRef
11.
go back to reference Chen M, Zhuang C, Liu Y, Li J, Dai F, Xia M et al. Tetracycline-inducible shRNA targeting antisense long non-coding RNA HIF1A-AS2 represses the malignant phenotypes of bladder cancer. Cancer Lett 2016;376:155–164CrossRef Chen M, Zhuang C, Liu Y, Li J, Dai F, Xia M et al. Tetracycline-inducible shRNA targeting antisense long non-coding RNA HIF1A-AS2 represses the malignant phenotypes of bladder cancer. Cancer Lett 2016;376:155–164CrossRef
12.
go back to reference Guo X, Lee S, Cao P. The inhibitive effect of sh-HIF1A-AS2 on the proliferation, invasion, and pathological damage of breast cancer via targeting miR-548c-3p through regulating HIF-1 alpha/VEGF pathway in vitro and vivo. Onco Targets Ther 2019;12:825–834CrossRef Guo X, Lee S, Cao P. The inhibitive effect of sh-HIF1A-AS2 on the proliferation, invasion, and pathological damage of breast cancer via targeting miR-548c-3p through regulating HIF-1 alpha/VEGF pathway in vitro and vivo. Onco Targets Ther 2019;12:825–834CrossRef
13.
go back to reference Lin J, Shi Z, Yu Z, He Z. LncRNA HIF1A-AS2 positively affects the progression and EMT formation of colorectal cancer through regulating miR-129-5p and DNMT3A. Biomed Pharmacother 2018;98:433–439CrossRef Lin J, Shi Z, Yu Z, He Z. LncRNA HIF1A-AS2 positively affects the progression and EMT formation of colorectal cancer through regulating miR-129-5p and DNMT3A. Biomed Pharmacother 2018;98:433–439CrossRef
15.
go back to reference Wang Z, Zhu Z, Lin Z, Luo Y, Liang Z, Zhang C et al. miR-429 suppresses cell proliferation, migration and invasion in nasopharyngeal carcinoma by downregulation of TLN1. Cancer Cell Int 2019;19:115CrossRef Wang Z, Zhu Z, Lin Z, Luo Y, Liang Z, Zhang C et al. miR-429 suppresses cell proliferation, migration and invasion in nasopharyngeal carcinoma by downregulation of TLN1. Cancer Cell Int 2019;19:115CrossRef
16.
go back to reference Farazi TA, Hoell JI, Morozov P, Tuschl T. MicroRNAs in human cancer. Adv Exp Med Biol 2013;774:1–20CrossRef Farazi TA, Hoell JI, Morozov P, Tuschl T. MicroRNAs in human cancer. Adv Exp Med Biol 2013;774:1–20CrossRef
17.
go back to reference Liu D, Xia P, Diao D, Cheng Y, Zhang H, Yuan D et al. MiRNA-429 suppresses the growth of gastric cancer cells in vitro. J Biomed Res 2012;26:389–393CrossRef Liu D, Xia P, Diao D, Cheng Y, Zhang H, Yuan D et al. MiRNA-429 suppresses the growth of gastric cancer cells in vitro. J Biomed Res 2012;26:389–393CrossRef
18.
go back to reference Ni J, Yang Y, Liu D, Sun H, Jin S, Li J. MicroRNA-429 inhibits gastric cancer migration and invasion through the downregulation of specificity protein 1. Oncol Lett 2017;13:3845–3849CrossRef Ni J, Yang Y, Liu D, Sun H, Jin S, Li J. MicroRNA-429 inhibits gastric cancer migration and invasion through the downregulation of specificity protein 1. Oncol Lett 2017;13:3845–3849CrossRef
19.
go back to reference Zhang M, Dong BB, Lu M, Zheng MJ, Chen H, Ding JZ et al. miR-429 functions as a tumor suppressor by targeting FSCN1 in gastric cancer cells. Onco Targets Ther 2016;9:1123–1133PubMedPubMedCentral Zhang M, Dong BB, Lu M, Zheng MJ, Chen H, Ding JZ et al. miR-429 functions as a tumor suppressor by targeting FSCN1 in gastric cancer cells. Onco Targets Ther 2016;9:1123–1133PubMedPubMedCentral
20.
go back to reference Zhu P, Zhang J, Zhu J, Shi J, Zhu Q, Gao Y. MiR-429 induces gastric carcinoma cell apoptosis through Bcl-2. Cell Physiol Biochem 2015;37:1572–1580CrossRef Zhu P, Zhang J, Zhu J, Shi J, Zhu Q, Gao Y. MiR-429 induces gastric carcinoma cell apoptosis through Bcl-2. Cell Physiol Biochem 2015;37:1572–1580CrossRef
21.
go back to reference Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 2013;5:200ra116CrossRef Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 2013;5:200ra116CrossRef
22.
go back to reference Yoo SH, Keam B, Ock CY, Kim S, Han B, Kim JW et al. Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients. Sci Rep 2019;9:7680CrossRef Yoo SH, Keam B, Ock CY, Kim S, Han B, Kim JW et al. Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients. Sci Rep 2019;9:7680CrossRef
23.
go back to reference Zhu H, Zhao H, Zhang L, Xu J, Zhu C, Zhao H et al. Dandelion root extract suppressed gastric cancer cells proliferation and migration through targeting lncRNA-CCAT1. Biomed Pharmacother 2017;93:1010–1017CrossRef Zhu H, Zhao H, Zhang L, Xu J, Zhu C, Zhao H et al. Dandelion root extract suppressed gastric cancer cells proliferation and migration through targeting lncRNA-CCAT1. Biomed Pharmacother 2017;93:1010–1017CrossRef
24.
go back to reference Gu X, Gao XS, Ma M, Qin S, Qi X, Li X et al. Prognostic significance of osteopontin expression in gastric cancer: a meta-analysis. Oncotarget 2016;7:69666–69673CrossRef Gu X, Gao XS, Ma M, Qin S, Qi X, Li X et al. Prognostic significance of osteopontin expression in gastric cancer: a meta-analysis. Oncotarget 2016;7:69666–69673CrossRef
26.
go back to reference Sun M, Nie F, Wang Y, Zhang Z, Hou J, He D et al. LncRNA HOXA11-AS promotes proliferation and invasion of gastric cancer by scaffolding the chromatin modification factors PRC2, LSD1, and DNMT1. Cancer Res 2016;76:6299–6310CrossRef Sun M, Nie F, Wang Y, Zhang Z, Hou J, He D et al. LncRNA HOXA11-AS promotes proliferation and invasion of gastric cancer by scaffolding the chromatin modification factors PRC2, LSD1, and DNMT1. Cancer Res 2016;76:6299–6310CrossRef
27.
go back to reference Wang MW, Liu J, Liu Q, Xu QH, Li TF, Jin S et al. LncRNA SNHG7 promotes the proliferation and inhibits apoptosis of gastric cancer cells by repressing the P15 and P16 expression. Eur Rev Med Pharmacol Sci 2017;21:4613–4622PubMed Wang MW, Liu J, Liu Q, Xu QH, Li TF, Jin S et al. LncRNA SNHG7 promotes the proliferation and inhibits apoptosis of gastric cancer cells by repressing the P15 and P16 expression. Eur Rev Med Pharmacol Sci 2017;21:4613–4622PubMed
28.
go back to reference Wei GH, Wang X. lncRNA MEG3 inhibit proliferation and metastasis of gastric cancer via p53 signaling pathway. Eur Rev Med Pharmacol Sci 2017;21:3850–3856PubMed Wei GH, Wang X. lncRNA MEG3 inhibit proliferation and metastasis of gastric cancer via p53 signaling pathway. Eur Rev Med Pharmacol Sci 2017;21:3850–3856PubMed
29.
go back to reference Xu MD, Wang Y, Weng W, Wei P, Qi P, Zhang Q et al. A Positive feedback loop of lncRNA-PVT1 and FOXM1 facilitates gastric cancer growth and invasion. Clin Cancer Res 2017;23:2071–2080CrossRef Xu MD, Wang Y, Weng W, Wei P, Qi P, Zhang Q et al. A Positive feedback loop of lncRNA-PVT1 and FOXM1 facilitates gastric cancer growth and invasion. Clin Cancer Res 2017;23:2071–2080CrossRef
30.
go back to reference Sun M, Jin FY, Xia R, Kong R, Li JH, Xu TP et al. Decreased expression of long noncoding RNA GAS5 indicates a poor prognosis and promotes cell proliferation in gastric cancer. BMC Cancer 2014;14:319CrossRef Sun M, Jin FY, Xia R, Kong R, Li JH, Xu TP et al. Decreased expression of long noncoding RNA GAS5 indicates a poor prognosis and promotes cell proliferation in gastric cancer. BMC Cancer 2014;14:319CrossRef
31.
go back to reference Cesana M, Cacchiarelli D, Legnini I, Santini T, Sthandier O, Chinappi M et al. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell 2011;147:358–369CrossRef Cesana M, Cacchiarelli D, Legnini I, Santini T, Sthandier O, Chinappi M et al. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell 2011;147:358–369CrossRef
32.
go back to reference Mao Y, Liu R, Zhou H, Yin S, Zhao Q, Ding X et al. Transcriptome analysis of miRNA-lncRNA-mRNA interactions in the malignant transformation process of gastric cancer initiation. Cancer Gene Ther 2017;24:267–275CrossRef Mao Y, Liu R, Zhou H, Yin S, Zhao Q, Ding X et al. Transcriptome analysis of miRNA-lncRNA-mRNA interactions in the malignant transformation process of gastric cancer initiation. Cancer Gene Ther 2017;24:267–275CrossRef
33.
go back to reference Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med 2016;375:1767–1778CrossRef Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med 2016;375:1767–1778CrossRef
34.
go back to reference Boger C, Behrens HM, Mathiak M, Kruger S, Kalthoff H, Rocken C. PD-L1 is an independent prognostic predictor in gastric cancer of Western patients. Oncotarget 2016;7:24269–24283CrossRef Boger C, Behrens HM, Mathiak M, Kruger S, Kalthoff H, Rocken C. PD-L1 is an independent prognostic predictor in gastric cancer of Western patients. Oncotarget 2016;7:24269–24283CrossRef
35.
go back to reference Li J, Chen L, Xiong Y, Zheng X, Xie Q, Zhou Q et al. Knockdown of PD-L1 in human gastric cancer cells inhibits tumor progression and improves the cytotoxic sensitivity to CIK therapy. Cell Physiol Biochem 2017;41:907–920CrossRef Li J, Chen L, Xiong Y, Zheng X, Xie Q, Zhou Q et al. Knockdown of PD-L1 in human gastric cancer cells inhibits tumor progression and improves the cytotoxic sensitivity to CIK therapy. Cell Physiol Biochem 2017;41:907–920CrossRef
36.
go back to reference Wu Y, Cao D, Qu L, Cao X, Jia Z, Zhao T et al. PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer. Oncotarget 2017;8:64066–64082CrossRef Wu Y, Cao D, Qu L, Cao X, Jia Z, Zhao T et al. PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer. Oncotarget 2017;8:64066–64082CrossRef
Metadata
Title
HIF1A-AS2 Promotes the Proliferation and Metastasis of Gastric Cancer Cells Through miR-429/PD-L1 Axis
Authors
Linsong Mu
Yeli Wang
Hailong Su
Yang Lin
Wu Sui
Xiang Yu
Zhongchuan Lv
Publication date
01-12-2021
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 12/2021
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-020-06819-w

Other articles of this Issue 12/2021

Digestive Diseases and Sciences 12/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.